. Unlike traditional monoclonal antibodies that target a single receptor on a cancer cell, a bispecific antibody is engineered to bind to two different targets simultaneously. For HMN-372, these targets are: EGFR (Epidermal Growth Factor Receptor):
offers peer-reviewed articles regarding the bispecific mechanism of action and its impact on MET-dysregulated tumors. Information for Caregivers The American Cancer Society
Once HMN-372 binds to these receptors, it triggers the cell to pull them inside and break them down, effectively "disarming" the cancer cell. Immune Activation: HMN-372
maintains a comprehensive registry of all ongoing and completed studies involving JNJ-372 (HMN-372).
(also referred to as JNJ-61186372 ) refers to Amivantamab , a pioneering bispecific antibody used in the treatment of advanced cancers, specifically Non-Small Cell Lung Cancer (NSCLC). HMN-372: A Breakthrough in Targeted Cancer Therapy Information for Caregivers The American Cancer Society Once
HMN-372 is being investigated for the treatment of various genetic disorders, including:
, an investigational drug that has transitioned into the approved clinical therapy known as Amivantamab What is HMN-372? HMN-372 is a fully human bispecific antibody HMN-372: A Breakthrough in Targeted Cancer Therapy HMN-372
. Historically, patients with these mutations had very few effective treatment options because they did not respond well to standard EGFR inhibitors.